H.R. 2069 · 116th Congress
SPIKE Act
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 116th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
D
HorsfordSponsor10 cosponsors · 8 D, 2 R
R
Reed
TC
D
Cox
SW
D
Wild
EC
D
Case
CH
D
Houlahan
JR
D
Raskin
AS
D
Spanberger
EN
D
Norton
ES
D
Slotkin
BS
R
Steil1 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
Stopping the Pharmaceutical Industry from Keeping drugs Expensive Act or the SPIKE Act
What it does: CRS summary · Introduced in House · Apr 3, 2019
Stopping the Pharmaceutical Industry from Keeping drugs Expensive Act or the SPIKE Act
This bill requires the Centers for Medicare & Medicaid Services (CMS) to determine at least annually whether certain covered drugs under Medicare were subject to a price increase that exceeded specified thresholds. Drug manufacturers must submit justifications for such price increases to the CMS, subject to civil penalties. The bill's requirements do not apply to low-cost drugs, as identified by the CMS.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: SPIKE Act
Also known as: Stopping the Pharmaceutical Industry from Keeping drugs Expensive Act
Latest action (May 21, 2019): Subcommittee Hearings Held.
Policy area: Health · Origin: House · Introduced: Apr 3, 2019
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.